Liquidia Technologies, Inc. (LQDA)
| Market Cap | 129.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -58.17M |
| Shares Out | 37.76M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $2.90 |
| Previous Close | $2.99 |
| Change ($) | -0.09 |
| Change (%) | -3.01% |
| Day's Open | 2.98 |
| Day's Range | 2.73 - 2.98 |
| Day's Volume | 2,197,036 |
| 52-Week Range | 2.60 - 3.40 |
LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.
LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDA...
NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors ...
RESEARCH TRIANGLE PARK, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a direc...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors ...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors ar...
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective i...
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are ad...
CRL does not cite need for additional clinical studies
Stockholders Approve RareGen Acquisition
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comme...
Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q3 2020 Results - Earnings Call Transcript
- Raised $75 M illion through Underwritten Public Offering - Bolstered and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to...
Company Determines Unsolicited Offer does not Constitute Superior Proposal
Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET
Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET
Lead candidate LIQ861 has shown an equivalent safety profile to UTHR's Tyvaso, and is also a bit easier to use.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comme...
PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® PTAB Institutes Inter Partes Review Proceeding Against...
Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical...
Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020
RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
Steven Bariahtaris Appointed Interim Chief Financial Officer Steven Bariahtaris Appointed Interim Chief Financial Officer
Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q2 2020 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (Qo...
RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and comm...
RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.
Liquidia Technologies Inc. (NASDAQ: LQDA) has seen its share of news after an acquisition and a recent stock sale.
RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.
RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...
Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several ...
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents
RESEARCH TRIANGLE PARK, N.C., June 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and com...
Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and comm...
Liquidia Technologies' (LQDA) CEO Neal Fowler on Q1 2020 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and co...
RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and co...
Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q4 2019 Results - Earnings Call Transcript
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019.
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
As of late, it has definitely been a great time to be an investor in Liquidia.
About LQDA
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, a... [Read more...]
| Industry Biotechnology | IPO Date Jul 26, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol LQDA |
Financial Performance
In 2019, LQDA's revenue was $8.07 million, an increase of 198.20% compared to the previous year's $2.71 million. Losses were -$47.58 million, -10.45% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is 5.20, which is an increase of 79.31% from the latest price.